Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

被引：17

作者：

Dumas, Pierre-Yves ^{[1
]}

Raffoux, Emmanuel ^{[2
]}

Berard, Emilie ^{[3
]}

Bertoli, Sarah ^{[4
]}

Hospital, Marie-Anne ^{[5
]}

Heiblig, Mael ^{[6
]}

Desbrosses, Yohann ^{[7
]}

Bonmati, Caroline ^{[8
]}

Pautas, Cecile ^{[9
]}

Lambert, Juliette ^{[10
]}

Orvain, Corentin ^{[11
,12
]}

Banos, Anne ^{[13
]}

Pasquier, Florence ^{[14
]}

Peterlin, Pierre ^{[15
]}

Marchand, Tony ^{[16
]}

Uzunov, Madalina ^{[17
]}

Frayfer, Jamile ^{[18
]}

Turlure, Pascal ^{[19
]}

Cluzeau, Thomas ^{[20
]}

Jourdan, Eric ^{[21
]}

Himberlin, Chantal ^{[22
]}

Tavernier, Emmanuelle ^{[23
]}

Villate, Alban ^{[24
]}

Haiat, Stephanie ^{[25
]}

Chretien, Marie-Lorraine ^{[26
]}

Carre, Martin ^{[27
]}

Chantepie, Sylvain ^{[28
]}

Vaida, Ioana ^{[29
]}

Wemeau, Mathieu ^{[30
]}

Chebrek, Safia ^{[31
]}

Guillerm, Gaelle ^{[32
]}

Guieze, Romain ^{[33
,34
]}

Debarri, Houria ^{[35
]}

Gehlkopf, Eve ^{[36
]}

Laribi, Kamel ^{[37
]}

Marcais, Ambroise ^{[38
]}

Santagostino, Alberto ^{[39
]}

Bene, Marie-Christine ^{[40
]}

Mineur, Ariane ^{[1
]}

Pigneux, Arnaud ^{[1
]}

Dombret, Herve ^{[2
]}

Recher, Christian ^{[4
]}

机构：

[1] CHU Bordeaux, Serv Hematol Clin & Therapie Cellulaire, F-33000 Bordeaux, France

[2] Hop St Louis, AP HP, Serv Hematol Adultes, Paris, France

[3] Univ Toulouse III Paul Sabatier, Ctr Hosp Univ Toulouse, Serv Epidemiol, INSERM,CERPOP, Toulouse, France

[4] Univ Toulouse III Paul Sabatier, Ctr Hosp Univ Toulouse, Inst Univ Canc Toulouse Oncopole, Toulouse, France

[5] Inst Paoli Calmettes, Marseille, France

[6] Hosp Civils Lyon, Serv Hematol Clin, Hop Lyon Sud, Pierre Benite, France

[7] CHRU Jean Minjoz, Serv Hematol, F-25000 Besancon, France

[8] CHU Nancy Brabois, Serv Hematol, F-54500 Vandoeuvre Les Nancy, France

[9] CHU Henri Mondor, Serv Hematol Clin & Therapie Cellulaire, 1 Rue Gustave Eiffel, F-94010 Creteil, France

[10] Ctr Hosp Versailles, Serv Hematol, Le Chesnay, France

[11] CHU Angers, Serv Malad Sang, F-49000 Angers, France

[12] Nantes Univ, CRCI2NA, CNRS UMR 6075,Univ Angers, Inserm UMR 1307,Federat Hosp Univ Grand Ouest Leu, F-49000 Angers, France

[13] Ctr Hosp Cote Basque, Serv Hematol, F-64100 Bayonne, France

[14] Univ Paris Saclay, Dept Hematol, Gustave Roussy, Villejuif, France

[15] Nantes Univ Hosp, Hematol Dept, Nantes, France

[16] CHU Rennes, Serv Hematol Clin, F-35000 Rennes, France

[17] Hop La Pitie Salpetriere, Serv Hematol, Paris, France

[18] Hop Meaux, Serv Hematol, Meaux, France

[19] CHU Limoges, Serv Hematol Clin & Therapie Cellulaire, F-87000 Limoges, France

[20] Univ Cote Azur, Dept Hematol Clin, CHU Nice, Nice, France

[21] Nimes Univ Hosp, Dept Hematol, Nimes, France

[22] Ctr Hosp Univ Reims, Hop Robert Debre, Reims, France

[23] CHU St Etienne, Serv Hematol Clin & Therapie Cellulaire, F-42000 St Etienne, France

[24] CHRU Tours, Hematol & Therapie Cellulaire, Tours, France

[25] Ctr Hosp Sud Francilien, Serv Hematol Clin, Corbeil Essonnes, France

[26] CHU Dijon, Serv Hematol Clin, Dijon, France

[27] CHU Grenoble Alpes, Grenoble, France

[28] CHU Caen, IHBN, Serv Hematol Clin, Caen, France

[29] Ctr Hosp Rene Dubos, Serv Hematol & Therapie Cellulaire, Cergy Pontoise, France

[30] CH Roubaix, Serv Hematol, F-59100 Roubaix, France

[31] CH Avignon, Serv Oncohematol, Avignon, France

[32] CHU Brest, Hop Morvan, Serv Cancerol Hematol, Brest, France

[33] CHU Clermont Ferrand, Serv Hematol Clin & Therapie Cellulaire, Clermont Ferrand, France

[34] Univ Clermont Auvergne, EA 7453 CHELTER, Clermont Ferrand, France

[35] CHR Metz Thionville, Hop Mercy, Serv Hematol, Metz, France

[36] CHU Montpellier, Hop St Eloi, Serv Hematol Clin, F-34295 Montpellier, France

[37] Ctr Hosp Le Mans, Dept Haematol, Le Mans, France

[38] Univ Paris Cite, Hop Necker Enfants Malad, Assistance Publ Hop Paris, Serv Hematol Adultes, Paris, France

[39] CHT Troyes, Serv Hematol Clin, F-10000 Troyes, France

[40] Nantes Univ Hosp, Hematol Biol, Nantes, France

来源：

LEUKEMIA | 2023年 / 37卷 / 01期

关键词：

FLT3; MUTATIONS; CYTOGENETICS; DIAGNOSIS;

D O I：

10.1038/s41375-022-01742-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B), including 67 previously treated by intensive chemotherapy and midostaurin (cohort C). The main differences in patient characteristics in this study compared to the ADMIRAL trial were ECOG >= 2 (83.6% vs. 16.6%), FLT3-TKD mutation (21.0% vs. 8.5%), primary induction failure (15.0% vs. 40.0%) and line of treatment (beyond 2nd in 37.1% vs. 0.0%). The rates of composite complete remission, excluding those that occurred after hematopoietic stem cell transplantation (HSCT), were similar at respectively 25.4% and 27.5% in cohorts B and C. Median overall survival (OS) for these two groups was also similar at respectively 6.4 and 7.8 months. Multivariate analyses for prognostic factors associated with OS identified female gender (HR 1.61), adverse cytogenetic risk (HR 2.52), and allogenic HSCT after gilteritinib (HR 0.13). Although these patients were more heavily pretreated, these real-world data reproduce the results of ADMIRAL and provide new insights into the course of patients previously treated by intensive chemotherapy and midostaurin and beyond the 2nd line of treatment who can benefit from treatment in an outpatient setting.

引用

页码：91 / 101

页数：11

共 50 条

[21] Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study
Kugler, Eitan
Cohen, Inbar
Ram, Ron
Canaani, Jonathan
Amitai, Irina
Shargian, Liat
Nachmias, Boaz
Krayem, Baher
Frisch, Avraham
Levi, Itay
Akria, Luiza
Raanani, Pia
Wolach, Ofir
Kugler, Eitan
BLOOD, 2023, 142
[22] Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
Sugamori, Haruko
Lee, Takumi
Mitomi, Takeshi
Yamagishi, Chika
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (07) : 758 - 765
[23] Phase II Study of Midostaurin plus Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML)
Reinhardt, Dirk
Zwaan, Christian Michel
Hoenekopp, Albert
Niolat, Julie
Ifrah, Sophie
Noel-Baron, Florence
Locatelli, Franco
BLOOD, 2019, 134
[24] Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia
Fathi, Amir Tahmasb
Arevalo, Mabel
Gutierrez, Sonia
Molero, Antonieta
Sacilotto, Natalia
Limon, Ana E.
Faller, Douglas V.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
McCall, David
Roth, Michael
Mahadeo, Kris M.
Toepfer, Laurie
Nunez, Cesar
Short, Nicholas J.
Daver, Naval
Kadia, Tapan M.
DiNardo, Courtney
Yi, Joanna S.
Cuglievan, Branko
BLOOD ADVANCES, 2021, 5 (23) : 5215 - 5219
[26] Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)
Zeidan, Amer M.
Qi, Cynthia Z.
Pandya, Bhavik J.
Garnham, Andy
Yang, Hongbo
Shah, Manasee V.
BLOOD, 2019, 134
[27] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial
Perl, A. E.
Martinelli, G.
Cortes, J. E.
Neubauer, A.
Berman, E.
Paolini, S.
Montesinos, P.
Baer, M. R.
Larson, R. A.
Ustun, C.
Fabbiano, F.
Di Stasi, A.
Stuart, R.
Olin, R.
Kasner, M.
Ciceri, F.
Chou, W. -C.
Podoltsev, N.
Recher, C.
Yokoyama, H.
Hosono, N.
Yoon, S. -S.
Lee, J. -H.
Pardee, T.
Fathi, A. T.
Liu, C.
Liu, X.
Bahceci, E.
Levis, M. J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 295 - 295
[28] GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL
Perl, A. E.
Martinelli, G.
Cortes, J. E.
Neubauer, A.
Berman, E.
Paolini, S.
Montesinos, P.
Baer, M. R.
Larson, R. A.
Ustun, C.
Fabbiano, F.
Di Stasi, A.
Stuart, R.
Olin, R.
Kasner, M.
Ciceri, F.
Chou, W.
Podoltsev, N.
Recher, C.
Yokoyama, H.
Hosono, N.
Yoon, S.
Pardee, J. Lee T.
Fathi, A. T.
Liu, C.
Liu, X.
Bahceci, E.
Levis, M. J.
HAEMATOLOGICA, 2019, 104 : 2 - 2
[29] Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
Greco, Rosa
Imbergamo, Silvia
Pierdomenico, Elisabetta
Di Camillo, Barbara
Papayannidis, Cristina
Todisco, Elisabetta
Borlenghi, Erika
Fracchiolla, Nicola
Basilico, Claudia
Fumagalli, Monica
Zappasodi, Patrizia
Turrini, Mauro
Candoni, Anna
Lunghi, Monia
Musso, Maurizio
Vetro, Calogero
Guolo, Fabio
Mannina, Donato
Lico, Albana
Scattolin, Anna Maria
Nadali, Gianpaolo
Crugnola, Monica
Galimberti, Sara
Marchesi, Francesco
Metafuni, Elisabetta
di Toritto, Tommaso Caravita
Minotti, Clara
Musto, Pellegrino
Mancini, Valentina
Riva, Marta
Rizzo, Lorenzo
Grillo, Giovanni
Cairoli, Roberto
BLOOD, 2024, 144 : 5188 - 5189
[30] Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia
Chen, Nianci
Pan, Jiajia
Zhou, Yile
Mao, Liping
Lou, Yinjun
Qian, Jiejing
Xu, Gaixiang
Wei, Juying
Zhou, De
Shou, Lihong
Huang, Li
Yan, Minchao
Zeng, Hui
Fan, Cuihua
Wu, Gongqiang
Feng, Weiying
Tong, Hongyan
Jin, Jie
Wang, Huafeng
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (03) : 861 - 870

← 1 2 3 4 5 →